10-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K/A

Amendment No. 1

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended June 30, 2013

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission file number 001-35023

iBio, Inc.

(Exact name of registrant as specified in its charter)

Delaware	26-2797813
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
9 Innovation Way, Suite 100, Newark, DE	19711
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (302) 355-0650

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Name of exchange on which registered
Common Stock, $0.001 par value	NYSE MKT

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $18,250,000 as of December 31, 2012, based upon the closing sale price on the NYSE MKT of $0.62 per share reported for such date.

There were 56,692,095 shares of the registrant’s common stock issued and outstanding as of September 10, 2013.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive proxy statement for its 2013 Annual Meeting of Stockholders, to be filed with the Commission not later than 120 days after the close of the registrant’s fiscal year, are incorporated by reference, in whole or in part, into Part III, Items 10, 11, 12, 13 and 14 of this Annual Report on Form 10-K.

EXPLANATORY NOTE

iBio, Inc. (the “Company”) is filing this Amendment No. 1 (this “Form 10-K/A”) to the Company’s Annual Report on Form 10-K for the year ended June 30, 2013, filed with the Securities and Exchange Commission (“SEC”) on September 30, 2013 (the “Form 10-K”), for the sole purpose of furnishing a revised XBRL file which improves the accuracy of the data tags selected in accordance with the 2013 U.S. GAAP Financial Reporting Taxonomy.

No other changes have been made to the Form 10-K. This Form 10-K/A speaks as of the original date of the Form 10-K, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the Form 10-K.

2

PART IV

Item 15. Exhibits and Financial Statement Schedules.

(a) Exhibits and Index

(1) A list of the financial statements filed as part of this report is set forth in the index to financial statements at page F-1 and is incorporated herein by reference. *

(2) An index of exhibits incorporated by reference or filed with this Report is provided below:

Exhibit No.	Description
3.1	Certificate of Incorporation of the Company *
3.2	Certificate of Amendment of the Certificate of Incorporation of the Company *
3.3	First Amended and Restated Bylaws of the Company *
4.1	Form of Common Stock Certificate *
4.2	Form of Investor Warrant (2010) *
4.3	Form of Common Stock Purchase Warrant (2012) *
4.4	Form of Common Stock Purchase Warrant (2013) *
10.1	Form of Registration Rights Agreement (2010) *
10.2	Technology Transfer Agreement, dated as of January 1, 2004, between the Company and Fraunhofer USA Center for Molecular Biotechnology, Inc. as amended *
10.3	Ratification dated September 6, 2013 of Terms of Settlement by and between the Company and Fraunhofer USA Center for Molecular Biotechnology, Inc. *
23.1	Consent of Independent Registered Public Accounting Firm *
31.1	Certification of Periodic Report by Chief Executive Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
31.2	Certification of Periodic Report by Chief Financial Officer Pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
32.1	Certification of Periodic Report by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *
32.2	Certification of Periodic Report by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *
101	The following materials from iBio, Inc.’s Annual Report on Form 10-K for the year ended June 30, 2013, formatted in XBRL (Extensible Business Reporting Language): (i) Balance Sheets, (ii) Statements of Operations, (iii) Statements of Stockholders’ Equity, (iv) Statements of Cash Flow, and (v) Notes to Financial Statements +

* Previously filed or furnished as an exhibit to the Company’s Form 10-K for the year ended June 30, 2013, filed with the SEC on September 30, 2013.

+ Furnished herewith.

3

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	iBio, Inc.
	(Registrant)
Dated: October 4, 2013		/s/ Robert B. Kay
		Robert B. Kay Executive Chairman (Principal Executive Officer)

Dated: October 4, 2013	/s/ Scott Kain
	Scott Kain Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

4

XML

Warrant Derivative Liability

12 Months Ended

Jun. 30, 2013

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

10. Warrant Derivative Liability

As of June 30, 2013, approximately 5.0 million outstanding warrants for the purchase of the Company’s common stock, issued in August 2008 as part of the spin-off from Integrated BioPharma, Inc. and expired in August 2013 (the “August 2008 Warrants”), contained an anti-dilution provision which must be accounted for separately as a derivative liability and measured at fair value on a recurring basis. Changes in fair value are charged to other income or expense, as appropriate. The fair value of the warrant derivative liability is determined based on Level 2 inputs utilizing observable quoted prices for similar instruments in active markets and observable quoted prices for identical or similar instruments in markets that are not very active. Using the Black-Scholes option pricing model, the Company developed its own assumptions based on observable inputs and available market data to support the reported fair values of approximately $0 and $520,000 as of June 30, 2013 and 2012, respectively.

The following table summarizes the inputs and assumptions used to calculate the fair value of the warrant derivative liability:

	June 30,		June 30,
	2013		2012
Common stock price		$0.42		$0.76
Exercise price		$1.53 - $1.97		$1.82 - $2.34
Risk-free interest rate		0.04%		0.2%
Dividend yield		0%		0%
Volatility		97.9%		100.0%
Remaining contractual term (in years)		0.2		1.2

XML

Income Taxes (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Current - Federal and state	$ 0	$ 0
Deferred - Federal	(2,447)	(2,802)
Deferred - State	(366)	(417)
Total	(2,813)	(3,219)
Change in valuation allowance	2,813	3,219
Income tax expense	$ 0	$ 0

XML

Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Revenues	$ 1,007	$ 1,277
Operating expenses:
Research and development (related party of $424 and $4,216 for the years ended June 30, 2013 and 2012, respectively)	3,431	4,981
General and administrative (related party of $0 and $200 for the years ended June 30, 2013 and 2012, respectively)	4,243	5,623
Total operating expenses	7,674	10,604
Operating loss	(6,667)	(9,327)
Other income (expense):
Interest income	9	12
Interest expense (related party of $0 and $62 for the years ended June 30, 2013 and 2012, respectively)	(90)	(63)
Royalty income	34	34
Change in fair value of warrant derivative liability	520	3,668
Other	(4)	0
Net loss	$ (6,198)	$ (5,676)
Loss per common share - basic and diluted (in dollars per share)	$ (0.13)	$ (0.14)
Weighted-average shares outstanding - basic and diluted (in shares)	49,381	39,506

XML

Summary of Significant Accounting Policies

12 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies [Text Block]

3. Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies, a warrant derivative liability and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

Fixed Assets

Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally three to five years.

Intangible Assets

The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 18 to 23 years. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges for the year ended June 30, 2013. For the year ended June 30, 2012, the Company recorded an impairment charge of approximately $0.1 million which is included in general and administrative expenses in the accompanying Statements of Operations.

Derivative Instruments

The Company does not use derivative instruments in its ordinary course of business. Some of the Company’s outstanding warrants contain an anti-dilution provision which qualifies as an embedded derivative and must be accounted for separately as a derivative liability. This liability is recognized on the balance sheet at fair value each reporting period, and changes in the fair value are charged to other income or expense, as appropriate, and reflected in the current period earnings.

Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured.

Research and Development Costs

All research and development costs are expensed as incurred. These expenses consist primarily of payments to third-party contractual service providers and internal personnel costs.

Share-based Compensation

The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates.

The impact that share-based payment awards will have on the Company’s results of operations is a function of the number of shares awarded, the trading price of the Company’s stock at the date of grant or modification, and the vesting schedule. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company’s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value. Expected volatility is based on historical volatility of the Company’s common stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company’s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations.

Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of June 30, 2013 and 2012. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2013 and 2012.

XML

Subsequent Events

12 Months Ended

Jun. 30, 2013

Subsequent Events [Abstract]

Subsequent Events [Text Block]

17. Subsequent Events

iBioDefense Biologics LLC

In July 2013, the Company created a wholly-owned subsidiary called iBioDefense Biologics LLC (“iBioDefense”) to explore development and commercialization of defense-specific applications of its proprietary technology. iBioDefense currently has no assets, liabilities, revenues or expenses.

Expiration of August 2008 Warrants

In August 2013, approximately 5 million outstanding warrants, comprising those originally issued in August 2008 as part of the spin-off from Integrated BioPharma, Inc. and those issued subsequently in accordance with the anti-dilution provision, expired prior to being exercised.

Fraunhofer Settlement Agreement

In September 2013, the Company and Fraunhofer completed the Terms of Settlement for the TTA Seventh Amendment (the “Settlement Agreement”), the significant terms of which are as follows:

· The Company’s liabilities to Fraunhofer in the amount of approximately $2.9 million as of June 30, 2013 were released and terminated;

· The term of the TTA has been extended by one year and will now expire on December 31, 2015;

· The Company’s obligation under the TTA, prior to the Settlement Agreement, to make three $1 million payments to Fraunhofer in April 2013, November 2013, and April 2014 was terminated and replaced with an obligation to engage Fraunhofer to perform at least $3 million of research and development work as directed by iBio prior to December 31, 2015;

· The Company terminated and released Fraunhofer from the obligation to make further financial contributions toward the enhancement, improvement and expansion of iBio’s technology in an amount at least equal to the Guaranteed Annual Payments. In addition, the Company terminated and released Fraunhofer from the obligation to further reimburse iBio for certain past and future patent-related expenses;

· The Company’s obligation to remit to Fraunhofer minimum annual royalty payments in the amount of $200,000 was terminated. Instead the Company will be obligated to remit royalties to Fraunhofer only on technology license revenues that iBio actually receives and on revenues from actual sales by iBio of products derived from the Company’s technology until the later of November 2023 or until such time as the aggregate royalty payments total at least $4 million;

· The rate at which the Company will be obligated to pay royalties to Fraunhofer on iBioLaunch and iBioModulator license revenues received was reduced from 15% to 10%; and

· Any and all other claims of each party to any other amounts due at June 30, 2013 were mutually released.

The effect of the Settlement Agreement will be the elimination of approximately $2.9 million of liabilities from the Company’s books, as well as a $1 million reduction in prepaid expenses and an approximately $1.9 million positive impact on earnings resulting from the reversal of expenses accrued by the Company under the terms of the previous agreement, and will be reflected in the Company’s financial statements for the quarter ending September 30, 2013. As of September 2013, the Company has entered into research services agreements with Fraunhofer representing approximately $1.8 million of the $3 million commitment described above. Based on the timelines established between the parties upon signing of the agreements, this work is expected to be completed by late 2014.

XML

Income Taxes (Details Textual) (USD $)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2008
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$ 28,900,000		$ 5,500,000
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	17,700,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	$ 737,000	$ 400,000

XML

Stockholders' Equity

12 Months Ended

Jun. 30, 2013

Stockholders Equity Note [Abstract]

Stockholders Equity Note Disclosure [Text Block]

11. Stockholders’ Equity

Preferred Stock

The Company’s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 1 million shares of preferred stock. The Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. As of June 30, 2013, there were no shares of preferred stock issued and outstanding.

Common Stock

As of June 30, 2013, the Company was authorized to issue up to 100 million shares of common stock, of which approximately 56.7 million shares were issued and outstanding. As of June 30, 2013, the Company had reserved up to 10 million shares of common stock for incentive compensation (stock options and restricted stock) and approximately 25.4 million shares of common stock for the exercise of warrants.

Warrants

The Company has historically financed its operations through the sale of common stock and warrants, sold together as units. The financing transactions reflected in the accompanying financial statements are described in detail below.

The following table summarizes all warrant activity for the year ended June 30, 2013:

	Warrants		Weighted- average Exercise Price
Outstanding as of June 30, 2012		20,940,796	$	1.39
Granted - consulting services		100,000	$	1.00	(1)
Granted - April 2013 equity offering		3,570,000	$	0.53
Granted – Anti-dilution adjustment on August 2008 warrants		785,144	$	1.75
Outstanding as of June 30, 2013		25,395,940	$	1.23	(2)
Exercisable as of June 30, 2013		25,395,940	$	1.23	(2)

(1) See Note 13 – Share-based Compensation

(2) Includes the effect of reduction in exercise price for previously granted August 2008 warrants.

April 2013 Equity Offering

On April 26, 2013, the Company, under its effective Registration Statement on Form S-3 (File No. 333-175420) (the “Registration Statement”), raised approximately $3.8 million in net proceeds by issuing 8,925,000 shares of common stock and warrants to purchase up to 3,570,000 shares of common stock. The common stock and warrants were sold together as units (the “2013 Units”), with each 2013 Unit consisting of one share of common stock and 0.40 (or 4/10ths) of one warrant to purchase one share of common stock. The public offering price of each 2013 Unit was $0.48. The warrants have an exercise price of $0.53 per share, are immediately exercisable and will expire on the third anniversary of the date of issuance.

Prior to this offering, there were outstanding approximately 4.2 million August 2008 Warrants. In connection with this offering, the anti-dilution provision was triggered and the Company was required to both increase the number of shares issuable upon exercise and decrease the exercise prices of the August 2008 Warrants. As a result, the number of August 2008 Warrants outstanding increased by approximately 0.8 million and the exercise prices decreased from $1.82 and $2.34 per share to $1.53 and $1.97 per share, respectively. After this adjustment, there were outstanding approximately 2.5 million warrants with an exercise price of $1.53 per share and approximately 2.5 million warrants with an exercise price of $1.97 per share. There was no change in the expiration date of the August 2008 Warrants as a result of this adjustment. See Note 17 – Subsequent Events regarding the expiration of the August 2008 Warrants in August 2013.

January 2013 ATM Facility

On January 31, 2013, the Company entered into an At-the-Market Equity Offering Sales Agreement (the “ATM Facility”) with Further Lane Securities, L.P. (“Further Lane”) pursuant to which the Company could sell, at its option, up to an aggregate of $10 million in shares of its common stock through Further Lane, as sales agent. The Company agreed to pay Further Lane a commission equal to 3% of the gross proceeds from the sale of shares of its common stock under the ATM Facility, if any. The Company also agreed to reimburse Further Lane for certain expenses incurred in connection with entering into the ATM Facility and provided Further Lane with customary indemnification rights.

There were no sales of the Company’s common stock pursuant to the ATM Facility during the year ended June 30, 2013. The Company incurred legal, accounting and filing fees of approximately $121,000, including expenses reimbursed to Further Lane, in connection with entry into the ATM Facility. As a result of the Company’s decision to move forward with an alternate financing strategy that effectively eliminated the capacity under the Registration Statement necessary to utilize the ATM Facility, these costs were charged to general and administrative expenses for the three months ended March 31, 2013. On April 26, 2013, the Company voluntarily terminated the ATM Facility prior to making any sales of its common stock under such agreement.

January 2012 Equity Offering

On January 13, 2012, the Company, under its effective Registration Statement, raised approximately $9.0 million in net proceeds by issuing 15,385,000 shares of common stock and warrants to purchase up to 11,538,750 shares of common stock. The common stock and warrants were sold together as units (the “2012 Units”), with each 2012 Unit consisting of one share of common stock and 0.75 (or 3/4ths) of one warrant to purchase one share of common stock. The public offering price of each 2012 Unit was $0.65. The warrants have an exercise price of $0.88 per share, became exercisable on the first anniversary of the date issuance and will expire on the second anniversary of the date of issuance, which is January 13, 2014.

Prior to this offering, there were outstanding approximately 2.8 million August 2008 Warrants. In connection with this offering, the anti-dilution provision was triggered and the Company was required to both increase the number of shares issuable upon exercise and decrease the exercise prices of the August 2008 Warrants. As a result, the number of August 2008 Warrants outstanding increased by approximately 1.4 million and the exercise prices decreased from $2.68 and 3.45 per share to $1.82 and $2.34 per share, respectively. After this adjustment, there were outstanding approximately 2.1 million warrants with an exercise price of $1.82 and approximately 2.1 million warrants with an exercise price of $2.34 per share. There was no change in the expiration date of the August 2008 Warrants as a result of this adjustment. See Note 17 – Subsequent Events regarding the expiration of the August 2008 Warrants in August 2013.

XML

Loss Per Common Share (Details Textual) In Millions, unless otherwise specified	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Incremental Common Shares Attributable to Share-based Payment Arrangements	6.7	5.5
Incremental Common Shares Attributable to Call Options and Warrants	25.4	20.9

XML

Related Party Transactions (Details Textual) (USD $)	1 Months Ended	12 Months Ended
	Feb. 29, 2012	Jun. 30, 2013	Jun. 30, 2012
Accounts Payable, Related Parties, Current		$ 93,000	$ 2,524,000
Research and Development Expense		3,431,000	4,981,000
General and Administrative Expense		4,243,000	5,623,000
Interest Expense		90,000	63,000
Board Member Consulting [Member]
General and Administrative Expense		15,000	75,000
Share-based Goods and Nonemployee Services Transaction, Shares Approved for Issuance	60,000
Annual Fee Paid to Board of Director		10,000	10,000
Share-based Goods and Nonemployee Services Transaction Exercise Price	$ 0.93
Share-based Goods and Nonemployee Services Transaction Service Period	6 months
Vendor [Member]
Research and Development Expense		424,000	225,000
Fraunhofer Shared Employee [Member]
Research and Development Expense			3,991,000
General and Administrative Expense			200,000
Interest Expense			$ 100,000

XML

Intangible Assets (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2012
Finite-Lived Intangible Assets, Gross carrying value	$ 4,969	$ 4,784
Finite-Lived Intangible Assets, Accumulated Amortization	(2,256)	(1,922)
Net intangible assets	2,713	2,862
Intellectual Property [Member]
Finite-Lived Intangible Assets, Gross carrying value	3,100	3,100
Finite-Lived Intangible Assets, Accumulated Amortization	(1,465)	(1,309)
Patents [Member]
Finite-Lived Intangible Assets, Gross carrying value	1,869	1,684
Finite-Lived Intangible Assets, Accumulated Amortization	$ (791)	$ (613)

XML

Intangible Assets (Tables)

12 Months Ended

Jun. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets [Table Text Block]

The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):

	June 30, 2013		June 30, 2012
Intellectual property – gross carrying value	$	3,100	$	3,100
Patents – gross carrying value		1,869		1,684
		4,969		4,784
Intellectual property – accumulated amortization		(1,465)		(1,309)
Patents – accumulated amortization		(791)		(613)
		(2,256)		(1,922)
Net intangible assets	$	2,713	$	2,862

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

The estimated annual amortization expense for the next five years and thereafter is as follows (in thousands):

For the Year Ending June 30,
2014	$	343
2015		343
2016		328
2017		312
2018		288
Thereafter		1,099
Total	$	2,713

XML

Prepaid Expenses and Other Current Assets (Tables)

12 Months Ended

Jun. 30, 2013

Prepaid Expense and Other Assets, Current [Abstract]

Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]

Prepaid expenses and other current assets consist of the following (in thousands):

	June 30, 2013			June 30, 2012
Prepaid expenses - Fraunhofer - semi-annual TTA payments	$	1,000	(1)	$	667	(2)
Prepaid expenses - Fraunhofer - other R&D projects		106			0
Other prepaid expenses		77			74
Other receivables - Fraunhofer - reimbursable patent costs		0			179	(2)
Other current assets		31			5
Total prepaid expenses and other current assets	$	1,214		$	925

(1) See Note 17 – Subsequent Events for additional information.

(2) Related party balance for the year ended June 30, 2012. See Note 15 – Related Party Transactions for additional information.

XML

Stockholders' Equity (Details)				12 Months Ended
	Jun. 30, 2013		Jun. 30, 2012	Jun. 30, 2013 Consulting Services [Member]		Jun. 30, 2013 April 2013 Equity Offering [Member]	Jun. 30, 2013 Anti Dilution Adjustment On August 2008 Warrants [Member]
Warrants, Outstanding Beginning	25,395,940		20,940,796
Warrants, Granted				100,000		3,570,000	785,144
Warrants, Outstanding Ending	25,395,940		20,940,796
Warrants, Exercisable	25,395,940
Weighted-average Exercise Price, Outstanding Beginning	1.23	[1]	1.39
Weighted-average Exercise Price, Granted				1.00	[2]	0.53	1.75
Weighted-average Exercise Price, Outstanding Ending	1.23	[1]	1.39
Weighted-average Exercise Price, Exercisable	1.23	[1]

[1] Includes the effect of reduction in exercise price for previously granted August 2008 warrants.

[2] See Note 13 – Share-based Compensation

XML

Basis of Presentation (Details Textual) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Accumulated deficit	$ (37,536)	$ (31,338)
Net Cash Provided by (Used in) Operating Activities	(4,849)	(6,010)
Cash	$ 4,414	$ 5,624	$ 2,843

XML

Intangible Assets (Details Textual) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Amortization of Intangible Assets	$ 336	$ 323
Patents [Member]
Finite-Lived Intangible Asset, Useful Life	6 years
Intellectual Property [Member]
Finite-Lived Intangible Asset, Useful Life	11 years

XML

Share-Based Compensation (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Allocated Share-based Compensation Expense	$ 1,263	$ 2,683
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	192	191
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense	$ 1,071	$ 2,492

XML

Share-Based Compensation (Tables)

12 Months Ended

Jun. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table summarizes the components of share-based compensation expense in the Statements of Operations (in thousands):

	For the Years Ended June 30,
	2013		2012
Research and development	$	192	$	191
General and administrative		1,071		2,492
Total share-based compensation	$	1,263	$	2,683

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes all stock option activity for the year ended June 30, 2013:

	Stock Options		Weighted- average Exercise Price		Weighted- average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of June 30, 2012		5,510,000	$	1.56		8.1	$	494
Granted		1,330,000	$	1.02
Forfeited		(80,000)	$	1.55
Outstanding as of June 30, 2013		6,760,000	$	1.45		7.5	$	161
Vested and expected to vest as of June 30, 2013		6,736,548	$	1.45		7.5	$	161
Exercisable as of June 30, 2013		4,266,604	$	1.54		7.0	$	139

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:

	2013		2012
Risk-free interest rate		1.3% - 2.0%		0.2% - 2.2%
Dividend yield		0%		0%
Volatility		98.9% - 100.8%		94.8% - 101.0%
Expected term (in years)		9		9 - 10

XML

Accrued Expenses (Details Textual) (USD $)	Jun. 30, 2013	Jun. 30, 2012
Accounts Payable, Current	$ 2,401,000	$ 2,846,000
Minimum annual royalties due to Fraunhofer [Member]
Accounts Payable, Current		$ 500,000

XML

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Liquidity Disclosure [Policy Text Block]

Going Concern

Since its spin-off from Integrated BioPharma, Inc. in August 2008, the Company has incurred significant losses and negative cash flows from operations. As of June 30, 2013, the Company’s accumulated deficit was $37.5 million, and it had cash used in operating activities of $4.8 million and $6.0 million for the years ended June 30, 2013 and 2012, respectively. The Company has historically financed its activities through the sale of common stock and warrants. Through June 30, 2013, the Company has dedicated most of its financial resources to investing in its iBioLaunch™ and iBioModulator™ platforms, advancing its intellectual property, and general and administrative activities. Cash on hand as of June 30, 2013 of $4.4 million, considering the effects of the Settlement Agreement completed in September 2013, is expected to support the Company’s activities through the third quarter of the fiscal year ending June 30, 2014. See Note 17 - Subsequent Events for additional information.

The history of significant losses, the negative cash flow from operations, the limited cash resources currently on hand and the dependence by the Company on its ability - about which there can be no certainty - to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company’s ability to continue as a going concern. These financial statements were prepared under the assumption that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.

The Company plans to fund its future business operations using cash on hand, through proceeds from the sale of additional equity or other securities and through proceeds realized in connection with license and collaboration arrangements. The Company cannot be certain that such funding will be available on favorable terms, or available at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience significant dilution. If the Company is unable to raise funds when required or on favorable terms, it may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of its proprietary technologies; b) seek collaborators for its technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that it would otherwise seek to develop or commercialize; or d) possibly cease operations. See Part I, Item 1A of this Annual Report on Form 10-K for a more detailed discussion of risks.

Reclassification, Policy [Policy Text Block]

Reclassifications

Certain prior-period amounts have been reclassified to conform to the current period presentation. Prepaid expenses and other current assets have been combined for presentation in the accompanying balance sheets and statements of cash flows. Depreciation and amortization expenses have been separated in the accompanying statements of cash flows. Share-based compensation expenses have been combined in the accompanying statements of cash flows.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies, a warrant derivative liability and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.

Property, Plant and Equipment, Policy [Policy Text Block]

Fixed Assets

Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally three to five years.

Goodwill and Intangible Assets, Policy [Policy Text Block]

Intangible Assets

The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 18 to 23 years. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges for the year ended June 30, 2013. For the year ended June 30, 2012, the Company recorded an impairment charge of approximately $0.1 million which is included in general and administrative expenses in the accompanying Statements of Operations.

Derivatives, Reporting of Derivative Activity [Policy Text Block]

Derivative Instruments

The Company does not use derivative instruments in its ordinary course of business. Some of the Company’s outstanding warrants contain an anti-dilution provision which qualifies as an embedded derivative and must be accounted for separately as a derivative liability. This liability is recognized on the balance sheet at fair value each reporting period, and changes in the fair value are charged to other income or expense, as appropriate, and reflected in the current period earnings.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured.

Research, Development, and Computer Software, Policy [Policy Text Block]

Research and Development Costs

All research and development costs are expensed as incurred. These expenses consist primarily of payments to third-party contractual service providers and internal personnel costs.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Share-based Compensation

The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance period. The Company uses historical data to estimate forfeiture rates.

The impact that share-based payment awards will have on the Company’s results of operations is a function of the number of shares awarded, the trading price of the Company’s stock at the date of grant or modification, and the vesting schedule. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company’s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value. Expected volatility is based on historical volatility of the Company’s common stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company’s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero.

Income Tax, Policy [Policy Text Block]

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations.

Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of June 30, 2013 and 2012. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as income tax expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended June 30, 2013 and 2012.

XML

Statements of Stockholders' Equity (USD $) In Thousands, except Share data	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Jun. 30, 2011	$ 196	$ 32	$ 25,826	$ (25,662)
Balance (in shares) at Jun. 30, 2011		32,382
Net loss	(5,676)	0	0	(5,676)
Share-based compensation	2,612	0	2,612	0
Issuance of common stock in connection with equity offering, net of expenses	9,037	16	9,021	0
Issuance of common stock in connection with equity offering, net of expenses (in shares)		15,385
Balance at Jun. 30, 2012	6,169	48	37,459	(31,338)
Balance (in shares) at Jun. 30, 2012		47,767
Net loss	(6,198)	0	0	(6,198)
Share-based compensation	1,263	0	1,263	0
Issuance of common stock in connection with equity offering, net of expenses	3,834	9	3,825	0
Issuance of common stock in connection with equity offering, net of expenses (in shares)		8,925
Balance at Jun. 30, 2013	$ 5,068	$ 57	$ 42,547	$ (37,536)
Balance (in shares) at Jun. 30, 2013		56,692

XML

Nature of Business

12 Months Ended

Jun. 30, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations [Text Block]

1. Nature of Business

iBio, Inc. (“iBio” or the “Company”) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies - the iBioLaunch™ platform for vaccines and therapeutic proteins and the iBioModulator™ platform for vaccine enhancement – and on developing and commercializing select product candidates derived from the iBioLaunch platform. The advantages of iBio’s technology include the ability to manufacture therapeutic proteins that are difficult or impossible to produce with conventional methods, reduced production time, and lower capital and operating costs for biopharmaceuticals. iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman, and its operations and assets reside exclusively in the United States.

XML

New Accounting Pronouncements

12 Months Ended

Jun. 30, 2013

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

New Accounting Pronouncements and Changes in Accounting Principles [Text Block]

4. New Accounting Pronouncements

The Financial Accounting Standards Board (“FASB”) recently issued Accounting Standards Update (“ASU”) No. 2012-04, Technical Corrections and Improvements. This ASU is part of an on-going project on the FASB’s agenda to facilitate Codification updates for non-substantive technical corrections, clarifications and improvements. The amendments are not expected to result in pervasive changes to accounting practices. However, because certain clarified guidance may cause a change to existing practice, the FASB provided special transition provisions for those amendments. For public entities, the amendments that are subject to the transition guidance are effective for fiscal periods beginning after December 15, 2012. The adoption of ASU No. 2012-04 is not expected to have a material effect on the Company’s financial statements.

The FASB also recently issued ASU No. 2013-07, Liquidation Basis of Accounting. This ASU provides guidance to entities about how and when to apply the liquidation basis of accounting. The ASU requires an entity to prepare its financial statements using the liquidation basis of accounting when liquidation is imminent, as defined in the ASU. Applying the liquidation basis of accounting requires an entity to measure its assets at the estimated amount of cash it expects to collect and its liabilities at the amount otherwise prescribed under U.S. GAAP. The ASU is effective for public entities that determine liquidation is imminent during annual reporting periods beginning after December 15, 2013 and interim reporting periods within those annual periods. An entity preparing its financial statements on a going-concern basis at the effective date that is required to use the liquidation basis of accounting is required to account for any differences between its existing measurements and the measurements under the ASU through a cumulative-effect adjustment. Early adoption is permitted.

As of June 30, 2013, the Company’s financial statements were prepared under the assumption that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. If circumstances change and it becomes necessary to apply the liquidation basis of accounting prior to the fiscal year beginning July 1, 2014, the Company will choose early adoption of ASU No. 2013-07.

XML

Basis of Presentation

12 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

2. Basis of Presentation

Going Concern

Since its spin-off from Integrated BioPharma, Inc. in August 2008, the Company has incurred significant losses and negative cash flows from operations. As of June 30, 2013, the Company’s accumulated deficit was $37.5 million, and it had cash used in operating activities of $4.8 million and $6.0 million for the years ended June 30, 2013 and 2012, respectively. The Company has historically financed its activities through the sale of common stock and warrants. Through June 30, 2013, the Company has dedicated most of its financial resources to investing in its iBioLaunch™ and iBioModulator™ platforms, advancing its intellectual property, and general and administrative activities. Cash on hand as of June 30, 2013 of $4.4 million, considering the effects of the Settlement Agreement completed in September 2013, is expected to support the Company’s activities through the third quarter of the fiscal year ending June 30, 2014. See Note 17 - Subsequent Events for additional information.

The history of significant losses, the negative cash flow from operations, the limited cash resources currently on hand and the dependence by the Company on its ability - about which there can be no certainty - to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company’s ability to continue as a going concern. These financial statements were prepared under the assumption that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.

The Company plans to fund its future business operations using cash on hand, through proceeds from the sale of additional equity or other securities and through proceeds realized in connection with license and collaboration arrangements. The Company cannot be certain that such funding will be available on favorable terms, or available at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience significant dilution. If the Company is unable to raise funds when required or on favorable terms, it may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of its proprietary technologies; b) seek collaborators for its technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that it would otherwise seek to develop or commercialize; or d) possibly cease operations. See Part I, Item 1A of this Annual Report on Form 10-K for a more detailed discussion of risks.

Reclassifications

Certain prior-period amounts have been reclassified to conform to the current period presentation. Prepaid expenses and other current assets have been combined for presentation in the accompanying balance sheets and statements of cash flows. Depreciation and amortization expenses have been separated in the accompanying statements of cash flows. Share-based compensation expenses have been combined in the accompanying statements of cash flows.

XML

Significant Vendor (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Accounts Payable, Current	$ 2,401,000	$ 2,846,000
Accrued Liabilities, Current	1,885,000	230,000
Research and Development Expense	3,431,000	4,981,000
Interest Expense	90,000	63,000
Fraunhofer [Member]
Accounts Payable, Current	2,200,000	2,500,000
Accrued Liabilities, Current	1,700,000	100,000
Research and Development Expense	2,700,000	4,200,000
Interest Expense	$ 88,000	$ 62,000

XML

Accrued Expenses (Tables)

12 Months Ended

Jun. 30, 2013

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued expenses consist of the following (in thousands):

	June 30, 2013			June 30, 2012
Fraunhofer – semi-annual TTA payment	$	1,000	(1)	$	-
Fraunhofer – minimum annual royalty		700	(1)		-	(2)
Fraunhofer – other R&D projects		-			100
Consulting fees		71			71
Public company costs		45			-
Salaries and benefits		44			41
Other accrued expenses		25			18
Total accrued expenses	$	1,885		$	230

(1) See Note 17 – Subsequent Events for additional information.

(2) The accounts payable balance as of June 30, 2012 included $500,000 of minimum annual royalties due to Fraunhofer.

XML

Income Taxes (Tables)

12 Months Ended

Jun. 30, 2013

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The components of the provision for income taxes consist of the following (in thousands):

	For the Years Ended June 30,
	2013		2012
Current - Federal and state	$	-	$	-
Deferred - Federal		(2,447)		(2,802)
Deferred - State		(366)		(417)
Total		(2,813)		(3,219)
Change in valuation allowance		2,813		3,219
Income tax expense	$	-	$	-

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

The components of the Company’s deferred tax assets and liabilities are as follows (in thousands): 

	As of June 30,
	2013		2012
Deferred tax assets (liabilities):
Net operating loss	$	10,856	$	8,532
Share-based compensation		3,198		2,682
Research and development tax credits		737		400
Accounts payable amounts not currently deductible		-		140
Intangible assets		(56)		172
Vacation accrual		18		14
Other		-		-
Valuation allowance		(14,753)		(11,940)
Total	$	-	$	-

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

A reconciliation of the statutory tax rate to the effective tax rate is as follows:

	Years Ended June 30,
	2013			2012
Statutory Federal income tax rate		34	%		34	%
State (net of Federal benefit)		6	%		6	%
Non-deductible expenses - change in fair value of derivative financial liability		3	%		26	%
Research and development tax credit		4	%		7	%
Non utilization of state operating loss (1)		-			(12)	%
Other		(2)	%		(4)	%
Change in valuation allowance		(45)	%		(57)	%
Effective income tax rate		0	%		0	%

(1) During the year ended June 30, 2012, the Company ceased doing business in a state and received a tax clearance. As a result, the cumulative net operating losses are not being recognized in the audited financial statements.

XML

Prepaid Expenses and Other Current Assets (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013		Jun. 30, 2012
Total prepaid expenses and other current assets	$ 1,214		$ 925
Prepaid expenses - Fraunhofer - semi-annual TTA payments [Member]
Total prepaid expenses and other current assets	1,000	[1]	667	[2]
Prepaid expenses - Fraunhofer - other R&D projects [Member]
Total prepaid expenses and other current assets	106		0
Other prepaid expenses [Member]
Total prepaid expenses and other current assets	77		74
Other receivables - Fraunhofer - reimbursable patent costs [Member]
Total prepaid expenses and other current assets	0		179	[2]
Other current assets [Member]
Total prepaid expenses and other current assets	$ 31		$ 5

[1] See Note 17 – Subsequent Events for additional information.

[2] Related party balance for the year ended June 30, 2012. See Note 15 – Related Party Transactions for additional information.

XML

Income Taxes (Details 2)	12 Months Ended
	Jun. 30, 2013		Jun. 30, 2012
Statutory Federal income tax rate	34.00%		34.00%
State (net of Federal benefit)	6.00%		6.00%
Non-deductible expenses - change in fair value of derivative financial liability	3.00%		26.00%
Research and development tax credit	4.00%		7.00%
Non utilization of state operating loss	0.00%	[1]	(12.00%)	[1]
Other	(2.00%)		(4.00%)
Change in valuation allowance	(45.00%)		(57.00%)
Effective income tax rate	0.00%		0.00%

[1] During the year ended June 30, 2012, the Company ceased doing business in a state and received a tax clearance. As a result, the cumulative net operating losses are not being recognized in the audited financial statements.

XML

Share-Based Compensation (Details 1) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Stock Options, Outstanding as of June 30, 2012	5,510,000
Stock Options, Granted	1,330,000
Stock Options, Forfeited	(80,000)
Stock Options, Outstanding as of June 30, 2013	6,760,000	5,510,000
Stock Options, Vested and expected to vest as of June 30, 2013	6,736,548
Stock Options, Exercisable as of June 30, 2013	4,266,604
Weighted-average Exercise Price, Outstanding as of June 30, 2012	$ 1.56
Weighted-average Exercise Price, Granted	$ 1.02
Weighted-average Exercise Price, Forfeited	$ 1.55
Weighted-average Exercise Price, Outstanding as of June 30, 2013	$ 1.45	$ 1.56
Weighted-average Exercise Price, Vested and expected to vest as of June 30, 2013	$ 1.45
Weighted-average Exercise Price, Exercisable as of June 30, 2013	$ 1.54
Weighted-average Remaining Contractual Term (in years), Outstanding	7 years 6 months	8 years 1 month 6 days
Weighted-average Remaining Contractual Term (in years), Vested and expected to vest as of June 30, 2013	7 years 6 months
Weighted-average Remaining Contractual Term (in years), Exercisable as of June 30, 2013	7 years
Aggregate Intrinsic Value, Outstanding	$ 161	$ 494
Aggregate Intrinsic Value, Vested and expected to vest as of June 30, 2013	161
Aggregate Intrinsic Value, Exercisable as of June 30, 2013	$ 139

XML

Warrant Derivative Liability (Details Textual) (USD $)	Jun. 30, 2013	Jun. 30, 2012
Derivative Liability, Current	$ 0	$ 520,000
Warrant [Member]
Warrants and Rights Outstanding	$ 5,000,000

XML

Balance Sheets (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2012
Prepaid expenses, related party (in dollars)	$ 0	$ 846
Accumulated depreciation (in dollars)	20	19
Accounts payable, related party (in dollars)	93	2,524
Accrued expenses, related party (in dollars)	$ 0	$ 100
Preferred stock,par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	56,692,095	47,767,095
Common stock, shares outstanding (in shares)	56,692,095	47,767,095

XML

Intangible Assets

12 Months Ended

Jun. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

7. Intangible Assets

The Company has two categories of intangible assets – intellectual property and patents. Intellectual property consists of technology for producing targeted proteins in plants for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications (the “Technology”) acquired in December 2003 from Fraunhofer USA Inc., acting through its Center for Molecular Biotechnology (“Fraunhofer”), pursuant to a Technology Transfer Agreement, as amended (the “TTA”). Patents consist of payments for services and fees related to the further development and protection of the Company’s patent portfolio.

The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):

	June 30, 2013		June 30, 2012
Intellectual property – gross carrying value	$	3,100	$	3,100
Patents – gross carrying value		1,869		1,684
		4,969		4,784
Intellectual property – accumulated amortization		(1,465)		(1,309)
Patents – accumulated amortization		(791)		(613)
		(2,256)		(1,922)
Net intangible assets	$	2,713	$	2,862

Amortization expense, included in general and administrative expenses, was approximately $336,000 and $323,000 for the years ended June 30, 2013 and 2012, respectively. The weighted-average remaining life for intellectual property and patents at June 30, 2013 was approximately 11 years and 6 years, respectively. The estimated annual amortization expense for the next five years and thereafter is as follows (in thousands):

For the Year Ending June 30,
2014	$	343
2015		343
2016		328
2017		312
2018		288
Thereafter		1,099
Total	$	2,713

XML

Statements of Operations (Parenthetical) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Interest expense, related party	$ 0	$ 62
Research and Development Expense [Member]
Operating expenses, related party	424	4,216
General and Administrative Expense [Member]
Operating expenses, related party	$ 0	$ 200

XML

Commitments and Contingencies (Details Textual) (USD $)	12 Months Ended
	Jun. 30, 2013	Sep. 06, 2013
Commitments and Contingencies
Long Term Purchase Commitment Total Payments	10,000,000
Long Term Purchase Commitment Payment Frequency	semi-annual
Long Term Purchase Commitment Payment Amount	1,000,000
Long-term Purchase Commitment, Time Period	15 years
Long-term Purchase Commitment, Amount	200,000
Fraunhofer [Member]
Commitments and Contingencies		$ 3,000,000
Long-term Purchase Commitment, Description	The TTA requires: 1) the Company, in consideration of Fraunhofer’s performance obligations, to make non-refundable payments to Fraunhofer totaling $10 million in semi-annual installments of $1 million commencing in November 2009; and 2) Fraunhofer to expend at least equal amounts during the same timeframe for research and development services related to the commercialization of the Technology.   Additionally, under the terms of the TTA and for a period of 15 years: 1) the Company shall pay Fraunhofer a defined percentage (per the agreement) of all receipts derived by the Company from sales of products produced utilizing the Technology and a defined percentage (per the agreement) of all receipts derived by the Company from licensing the Technology to third parties, with an overall minimum annual payment of $200,000 commencing on December 31, 2010; and 2) Fraunhofer shall pay the Company a defined percentage (per the agreement) of all receipts from sales, licensing, or commercialization of the Technology in developing countries as defined in the agreement. All new intellectual property invented by Fraunhofer during the period of the TTA is owned by and is required to be transferred to iBio.

XML

Balance Sheets (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2012
Assets
Cash	$ 4,414	$ 5,624
Accounts receivable - trade	1,007	351
Prepaid expenses and other current assets (related party of $0 and $846 as of June 30, 2013 and 2012, respectively)	1,214	925
Total current assets	6,635	6,900
Fixed assets, net of accumulated depreciation of $20 and $19 as of June 30, 2013 and 2012, respectively	6	3
Intangible assets, net	2,713	2,862
Total assets	9,354	9,765
Liabilities and Stockholders’ Equity
Accounts payable (related party of $93 and $2,524 as of June 30, 2013 and 2012, respectively)	2,401	2,846
Accrued expenses (related party of $0 and $100 as of June 30, 2013 and 2012, respectively)	1,885	230
Warrant derivative liability	0	520
Total liabilities	4,286	3,596
Commitments and contingencies
Stockholders’ equity:
Preferred stock - no par value; 1,000,000 shares authorized; no shares issued and outstanding as of June 30, 2013 and 2012	0	0
Common stock - $0.001 par value; 100,000,000 shares authorized; 56,692,095 and 47,767,095 shares issued and outstanding as of June 30, 2013 and 2012, respectively	57	48
Additional paid-in capital	42,547	37,459
Accumulated deficit	(37,536)	(31,338)
Total stockholders’ equity	5,068	6,169
Total liabilities and stockholders’ equity	$ 9,354	$ 9,765

XML

Share-Based Compensation (Details 2)	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Dividend yield	0.00%	0.00%
Expected term (in years)	9 years
Maximum [Member]
Risk-free interest rate	2.00%	2.20%
Volatility	100.80%	101.00%
Expected term (in years)		10 years
Minimum [Member]
Risk-free interest rate	1.30%	0.20%
Volatility	98.90%	94.80%
Expected term (in years)		9 years

XML

Warrant Derivative Liability (Tables)

12 Months Ended

Jun. 30, 2013

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]

The following table summarizes the inputs and assumptions used to calculate the fair value of the warrant derivative liability:

	June 30,		June 30,
	2013		2012
Common stock price		$0.42		$0.76
Exercise price		$1.53 - $1.97		$1.82 - $2.34
Risk-free interest rate		0.04%		0.2%
Dividend yield		0%		0%
Volatility		97.9%		100.0%
Remaining contractual term (in years)		0.2		1.2

XML

Commitments and Contingencies

12 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

16. Commitments and Contingencies

The Company’s commitments and contractual obligations to Fraunhofer described below, which existed as of and for the year ended June 30, 2013, have been significantly altered as a result of the events described in Note 17 – Subsequent Events. See Note 17 for discussion of $3 million of commitments through December 31, 2015.

The TTA requires Fraunhofer to provide the Company with research and development services related to the commercialization of the Technology and allows Fraunhofer to apply the Technology to the development and production of certain vaccines for use in developing countries as defined in the agreement. The TTA requires: 1) the Company, in consideration of Fraunhofer’s performance obligations, to make non-refundable payments to Fraunhofer totaling $10 million in semi-annual installments of $1 million commencing in November 2009; and 2) Fraunhofer to expend at least equal amounts during the same timeframe for research and development services related to the commercialization of the Technology.

Additionally, under the terms of the TTA and for a period of 15 years: 1) the Company shall pay Fraunhofer a defined percentage (per the agreement) of all receipts derived by the Company from sales of products produced utilizing the Technology and a defined percentage (per the agreement) of all receipts derived by the Company from licensing the Technology to third parties, with an overall minimum annual payment of $200,000 commencing on December 31, 2010; and 2) Fraunhofer shall pay the Company a defined percentage (per the agreement) of all receipts from sales, licensing, or commercialization of the Technology in developing countries as defined in the agreement. All new intellectual property invented by Fraunhofer during the period of the TTA is owned by and is required to be transferred to iBio.

XML

Warrant Derivative Liability (Details) (USD $)	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Common stock price (in dollars per share)	$ 0.42	$ 0.76
Risk-free interest rate	0.04%	0.20%
Dividend yield	0.00%	0.00%
Volatility	97.90%	100.00%
Remaining contractual term (in years)	2 months 12 days	1 year 2 months 12 days
Minimum [Member]
Exercise price (in dollars per share)	$ 1.53	$ 1.82
Maximum [Member]
Exercise price (in dollars per share)	$ 1.97	$ 2.34

XML

Income Taxes (Details 1) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2012
Deferred tax assets (liabilities):
Net operating loss	$ 10,856	$ 8,532
Share-based compensation	3,198	2,682
Research and development tax credits	737	400
Accounts payable amounts not currently deductible	0	140
Intangible assets	(56)	172
Vacation accrual	18	14
Valuation allowance	(14,753)	(11,940)
Total	$ 0	$ 0

XML

Intangible Assets (Details 1) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2012
2014	$ 343
2015	343
2016	328
2017	312
2018	288
Thereafter	1,099
Total	$ 2,713	$ 2,862

XML

Summary of Significant Accounting Policies (Details Textual) (General and Administrative Expense [Member], USD $) In Millions, unless otherwise specified	12 Months Ended
	Jun. 30, 2012
General and Administrative Expense [Member]
Asset Impairment Charges	$ 0.1

XML

Financial Instruments and Fair Value Measurement (Details Textual) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Jun. 30, 2012
Derivative Liability, Current	$ 0	$ 520

XML

Prepaid Expenses and Other Current Assets

12 Months Ended

Jun. 30, 2013

Prepaid Expense and Other Assets, Current [Abstract]

Prepaid Expenses and Other Current Assets [Text Block]

6. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):

	June 30, 2013			June 30, 2012
Prepaid expenses - Fraunhofer - semi-annual TTA payments	$	1,000	(1)	$	667	(2)
Prepaid expenses - Fraunhofer - other R&D projects		106			0
Other prepaid expenses		77			74
Other receivables - Fraunhofer - reimbursable patent costs		0			179	(2)
Other current assets		31			5
Total prepaid expenses and other current assets	$	1,214		$	925

(1) See Note 17 – Subsequent Events for additional information.

(2) Related party balance for the year ended June 30, 2012. See Note 15 – Related Party Transactions for additional information.

XML

Stockholders' Equity (Tables)

12 Months Ended

Jun. 30, 2013

Stockholders Equity Note [Abstract]

Schedule of Stockholders Equity Note, Warrants or Rights [Table Text Block]

The following table summarizes all warrant activity for the year ended June 30, 2013:

	Warrants		Weighted- average Exercise Price
Outstanding as of June 30, 2012		20,940,796	$	1.39
Granted - consulting services		100,000	$	1.00	(1)
Granted - April 2013 equity offering		3,570,000	$	0.53
Granted – Anti-dilution adjustment on August 2008 warrants		785,144	$	1.75
Outstanding as of June 30, 2013		25,395,940	$	1.23	(2)
Exercisable as of June 30, 2013		25,395,940	$	1.23	(2)

(1) See Note 13 – Share-based Compensation

(2) Includes the effect of reduction in exercise price for previously granted August 2008 warrants.

XML

Accrued Expenses (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013		Jun. 30, 2012
Total accrued expenses	$ 1,885		$ 230
Fraunhofer - semi-annual TTA payment [Member]
Total accrued expenses	1,000	[1]	0
Fraunhofer - minimum annual royalty [Member]
Total accrued expenses	700	[1]	0	[2]
Fraunhofer - other R&D projects [Member]
Total accrued expenses	0		100
Consulting fees [Member]
Total accrued expenses	71		71
Public company costs [Member]
Total accrued expenses	45		0
Salaries and benefits [Member]
Total accrued expenses	44		41
Other accrued expenses [Member]
Total accrued expenses	$ 25		$ 18

[1] See Note 17 – Subsequent Events for additional information.

[2] The accounts payable balance as of June 30, 2012 included $500,000 of minimum annual royalties due to Fraunhofer.

XML

Accrued Expenses

12 Months Ended

Jun. 30, 2013

Payables and Accruals [Abstract]

Accrued Expenses Disclosure [Text Block]

9. Accrued Expenses

Accrued expenses consist of the following (in thousands):

	June 30, 2013			June 30, 2012
Fraunhofer – semi-annual TTA payment	$	1,000	(1)	$	-
Fraunhofer – minimum annual royalty		700	(1)		-	(2)
Fraunhofer – other R&D projects		-			100
Consulting fees		71			71
Public company costs		45			-
Salaries and benefits		44			41
Other accrued expenses		25			18
Total accrued expenses	$	1,885		$	230

(1) See Note 17 – Subsequent Events for additional information.

(2) The accounts payable balance as of June 30, 2012 included $500,000 of minimum annual royalties due to Fraunhofer.

XML

Financial Instruments and Fair Value Measurement

12 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

5. Financial Instruments and Fair Value Measurement

The carrying values of cash, accounts receivable, prepaid expenses and other current assets, and accounts payable in the Company’s balance sheets approximated their fair values as of June 30, 2013 and 2012 due to their short-term nature. The warrant derivative liability is carried on the balance sheets at fair value, which was $0 and approximately $520,000 as of June 30, 2013 and 2012, respectively. See Note 10 - Warrant Derivative Liability for additional information.

XML

Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities:
Net loss	$ (6,198)	$ (5,676)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2	7
Amortization	336	323
Share-based compensation	1,263	2,683
Change in fair value of warrant derivative liability	(520)	(3,668)
Vendor concession - related party	0	100
Impairment of intangible assets	0	87
Other	3	0
Changes in operating assets and liabilities:
Increase in accounts receivable - trade	(656)	(7)
(Increase) decrease in prepaid expenses and other current assets	(289)	88
Decrease in accounts payable	(445)	(50)
Increase in accrued expenses	1,655	103
Net cash used in operating activities	(4,849)	(6,010)
Cash flows from investing activities:
Additions to intangible assets	(188)	(244)
Purchases of fixed assets	(7)	(1)
Net cash used in investing activities	(195)	(245)
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants, net of expenses	3,834	9,036
Net cash provided by financing activities	3,834	9,036
Net (decrease) increase in cash	(1,210)	2,781
Cash at beginning of year	5,624	2,843
Cash at end of year	$ 4,414	$ 5,624

XML

Share-Based Compensation (Details Textual) (USD $)	12 Months Ended				2 Months Ended	12 Months Ended				1 Months Ended
	Jun. 30, 2013		Jun. 30, 2012	Aug. 12, 2008	Dec. 31, 2011 Option Modification [Member]	Jun. 30, 2013 Option Modification [Member]	Jun. 30, 2012 Option Modification [Member]	Jun. 30, 2013 Board Of Directors And Officers [Member]	Jun. 30, 2012 Board Of Directors And Officers [Member]	Jul. 31, 2012 Investor Relations Services [Member]	Oct. 31, 2011 Investor Relations Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)	10,000,000			10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	3,200,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1.02							$ 1.01	$ 1.90
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.90		$ 1.56
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized (in Dollars)	$ 2,000,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	2 years 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,330,000							1,200,000	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	2,500,000		700,000							33,000	71,000
Effect in Fair Value of Options Due to Modification of Option Agreement Terms					633,000
Research and Development Expense	3,431,000		4,981,000			16,000	17,000
General and Administrative Expense	$ 4,243,000		$ 5,623,000			$ 49,000	$ 552,000
Class of Warrants or Rights Granted										100,000	100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	1.23	[1]	1.39							1.00	2.00
Class of Warrants or Rights Expiration Period										2 years	2 years

[1] Includes the effect of reduction in exercise price for previously granted August 2008 warrants.

XML

Stockholders' Equity (Details Textual) (USD $)	12 Months Ended				1 Months Ended					0 Months Ended
	Jun. 30, 2013		Jun. 30, 2012	Aug. 12, 2008	Apr. 26, 2013 April Equity Offering 2013 [Member]	Apr. 26, 2013 April Equity Offering 2013 [Member] Warrant One [Member] Before Antidilution Adjustment [Member]	Apr. 26, 2013 April Equity Offering 2013 [Member] Warrant One [Member] After Antidilution Adjustment [Member]	Apr. 26, 2013 April Equity Offering 2013 [Member] Warrant Two [Member] Before Antidilution Adjustment [Member]	Apr. 26, 2013 April Equity Offering 2013 [Member] Warrant Two [Member] After Antidilution Adjustment [Member]	Jan. 13, 2012 January Equity Offering 2012 [Member]	Apr. 26, 2013 January Equity Offering 2012 [Member] Warrant One [Member] Before Antidilution Adjustment [Member]	Apr. 26, 2013 January Equity Offering 2012 [Member] Warrant One [Member] After Antidilution Adjustment [Member]	Apr. 26, 2013 January Equity Offering 2012 [Member] Warrant Two [Member] Before Antidilution Adjustment [Member]	Apr. 26, 2013 January Equity Offering 2012 [Member] Warrant Two [Member] After Antidilution Adjustment [Member]
Preferred Stock, Shares Authorized	1,000,000		1,000,000
Common Stock, Shares Authorized	100,000,000		100,000,000
Common Stock, Shares, Issued	56,692,095		47,767,095
Common Stock, Shares, Outstanding	56,692,095		47,767,095
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	10,000,000			10,000,000
Proceeds from Issuance or Sale of Equity	$ 3,834,000		$ 9,036,000		$ 3,800,000					$ 9,000,000
Stock Issued During Period, Shares, Other					8,925,000					15,385,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					3,570,000					11,538,750
Shares Issued, Price Per Share					$ 0.48					$ 0.65
Class of Warrant or Right, Exercise Price of Warrants or Rights	1.23	[1]	1.39		0.53	1.82	1.53	2.34	1.97	0.88	2.68	1.82	3.45	2.34
Description of Units Sold					one share of common stock and 0.40 (or 4/10ths) of one warrant to purchase one share of common stock					one share of common stock and 0.75 (or 3/4ths) of one warrant to purchase one share of common stock
Class of Warrant or Right, Date from which Warrants or Rights Exercisable					Apr. 26, 2013					Jan. 13, 2013
Class of Warrant or Right, Outstanding	25,395,940		20,940,796			4,200,000	2,500,000		2,500,000	2,800,000		2,100,000		2,100,000
Class of Warrants or Rights Antidilution Adjustment						800,000
Class of Warrant or Right Increase in Numbers										$ 1,400,000

[1] Includes the effect of reduction in exercise price for previously granted August 2008 warrants.

XML

Nature of Business (Details Textual)	12 Months Ended
	Jun. 30, 2013
Number of Operating Segments	1

XML

Subsequent Events (Details Textual) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Jun. 30, 2013	Sep. 06, 2013 Fraunhofer [Member]
Long Term Purchase Commitment Expire Date	Dec. 31, 2015
Commitments and Contingencies		$ 3

XML

Loss Per Common Share

12 Months Ended

Jun. 30, 2013

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

12. Loss Per Common Share

Basic loss per common share is computed by dividing the net loss allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the year. For purposes of calculating diluted loss per common share, the denominator includes both the weighted-average number of shares of common stock outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method.

For the years ended June 30, 2013 and 2012, the Company incurred a net loss which cannot be diluted, so basic and diluted loss per common share are the same. As of June 30, 2013, shares issuable which could potentially dilute future earnings included approximately 6.7 million stock options and 25.4 million warrants. As of June 30, 2012, shares issuable which could potentially dilute future earnings included approximately 5.5 million stock options and 20.9 million warrants.

XML

Significant Vendor

12 Months Ended

Jun. 30, 2013

Significant Vendor [Abstract]

Significant Vendor Disclosures [Text Block]

8. Significant Vendor

As of June 30, 2013, Fraunhofer continued to be the Company’s most significant vendor. The Company has previously disclosed that Fraunhofer was considered a related party from February 2010 through February 2012 as a result of a Fraunhofer executive serving as iBio’s Chief Scientific Officer during such time. See Note 15 – Related Party Transactions for additional information. The accounts payable balance includes amounts due to Fraunhofer of approximately $2.2 million and $2.5 million as of June 30, 2013 and 2012, respectively. In addition, the accrued expenses balance includes amounts due to Fraunhofer of approximately $1.7 million and $0.1 million as of June 30, 2013 and 2012, respectively. Research and development expenses related to Fraunhofer were approximately $2.7 million and $4.2 million for the years ended June 30, 2013 and 2012, respectively. In addition, the Company is charged interest by Fraunhofer on certain outstanding balances at the rate of prime plus 2%. Interest expenses related to Fraunhofer were approximately $88,000 and $62,000 for the years ended June 30, 2013 and 2012, respectively. See Note 16 – Commitments and Contingencies and Note 17 – Subsequent Events for additional information.

XML

Related Party Transactions

12 Months Ended

Jun. 30, 2013

Related Party Transactions [Abstract]

Related Party Transactions Disclosure [Text Block]

15. Related Party Transactions

Fraunhofer - Shared Employee

From July 1, 2011 through February 29, 2012, the Company employed an executive of Fraunhofer as its Chief Scientific Officer. During this time, the Company had the following contractual arrangements in place with Fraunhofer:

⋅ The TTA, which requires the Company to make (1) semi-annual payments of $1 million for research and development services related to the commercialization of the Technology and (2) a minimum annual royalty payment, included in general and administrative expenses, of $200,000 to Fraunhofer. In addition, Fraunhofer is entitled to charge interest at the rate of prime plus 2% on certain unpaid balances. The interest expense for the year ended June 30, 2012 was approximately $0.1 million. The total expense recorded for the year ended June 30, 2012 was approximately $2.3 million. See Note 16 – Commitments and Contingencies for additional information.

⋅ In January 2011, the Company licensed its proprietary Technology to FioCruz/Bio-Manguinhos (“FioCruz”) of Brazil to develop, manufacture and sell certain vaccines. The Company engaged Fraunhofer as a contractor to provide the research and development services under license agreement to FioCruz on the Company’s behalf. The services are billed to FioCruz at Fraunhofer’s cost, so revenue is equivalent to expense and there is no profit. The revenue and expense for the year ended June 30, 2012 was approximately $1.3 million.

⋅ In December 2010, the Company and Fraunhofer entered into an approximately $1.7 million research services agreement to evaluate gene expression and protein production using the iBioLaunch platform. The expense recorded for the year ended June 30, 2012 was approximately $0.6 million.

⋅ In March 2011, the Company and Fraunhofer entered into an approximately $0.4 million research services agreement for the evaluation of the mechanism of immune-potentiating activity of lichenase (“LicKM”). The expense recorded for the year ended June 30, 2012 was approximately $0.3 million.

⋅ Pursuant to an agreement, Fraunhofer was required to reimburse the Company for certain costs incurred for patent protection of the Technology. The type and amount of costs to be reimbursed was an area of dispute between the parties. For the year ended June 30, 2012, the Company recorded a vendor concession of $0.1 million in general and administrative expenses to reduce the receivable to the agreed-upon settlement amount of approximately $0.2 million.

Research and Development Services Vendor

In January 2012, the Company entered into an agreement with a vendor in which iBio’s President is a minority stockholder. The vendor performs laboratory feasibility analyses of gene expression, protein purification and preparation of research samples. The transaction has been conducted on an arm’s length basis at market terms. The accounts payable balance includes amounts due to this vendor of approximately $93,000 and $64,000 as of June 30, 2013 and 2012, respectively. Research and development expenses related to this vendor were approximately $424,000 and $225,000 for the years ended June 30, 2013 and 2012, respectively.

Consulting Services by Board Member

In February 2012, the Company entered into a business development consulting agreement with a member of the Board of Directors. The six month agreement included monthly payments of $15,000 and 60,000 stock options which vested in six equal monthly installments of 10,000 options per month. The options have an exercise price of $0.93 per share and will expire ten years from the date of grant. The consulting expense, included in general and administrative expenses, for the years ended June 30, 2013 and 2012 was $15,000 and $75,000, respectively. Additionally, members of the Board of Directors receive $10,000 per year of cash compensation for their service to the Company.

XML

Share-Based Compensation

12 Months Ended

Jun. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

13. Share-Based Compensation

The following table summarizes the components of share-based compensation expense in the Statements of Operations (in thousands):

	For the Years Ended June 30,
	2013		2012
Research and development	$	192	$	191
General and administrative		1,071		2,492
Total share-based compensation	$	1,263	$	2,683

Stock Options

On August 12, 2008, the Company adopted the iBioPharma 2008 Omnibus Equity Incentive Plan (the “Plan”) for employees, officers, directors and external service providers. Under the provisions of the Plan, the Company may grant options to purchase stock and/or make awards of restricted stock up to an aggregate amount of 10 million shares. Stock options granted under the Plan may be either incentive stock options (as defined by Section 422 of the internal Revenue Code of 1986, as amended) or non-qualified stock options at the discretion of the Board of Directors. Vesting of awards occurs ratably on the anniversary of the grant date over the service period, generally three or five years, as determined at the time of grant. As of June 30, 2013, there were approximately 3.2 million shares of common stock reserved for future issuance under the Plan.

During the years ended June 30, 2013 and 2012, the Company granted stock options to members of the Board of Directors and officers to purchase approximately 1.2 million and 1.0 million shares of common stock, respectively. These options vest ratably on the anniversary of the date of grant over a three to five year service period, expire ten years from the date of grant, and have a weighted-average exercise price of $1.01 per share and $1.90 per share, respectively. See Note 15 – Related Party Transactions for additional information.

The following table summarizes all stock option activity for the year ended June 30, 2013:

	Stock Options		Weighted- average Exercise Price		Weighted- average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of June 30, 2012		5,510,000	$	1.56		8.1	$	494
Granted		1,330,000	$	1.02
Forfeited		(80,000)	$	1.55
Outstanding as of June 30, 2013		6,760,000	$	1.45		7.5	$	161
Vested and expected to vest as of June 30, 2013		6,736,548	$	1.45		7.5	$	161
Exercisable as of June 30, 2013		4,266,604	$	1.54		7.0	$	139

The total fair value of stock options that vested during the years ended June 30, 2013 and 2012 was approximately $2.5 million and $0.7 million, respectively. As of June 30, 2013, there was approximately $2.0 million of total unrecognized compensation cost related to stock options granted which the Company expects to recognize over a weighted-average period of 2.6 years.

The weighted-average grant date fair value of the stock options granted during the years ended June 30, 2013 and 2012 was $0.90 per share and $1.56 per share, respectively. The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:

	2013		2012
Risk-free interest rate		1.3% - 2.0%		0.2% - 2.2%
Dividend yield		0%		0%
Volatility		98.9% - 100.8%		94.8% - 101.0%
Expected term (in years)		9		9 - 10

In November and December 2011, the Board of Directors modified the cancellation provision of previously issued options, permitting an option holder, upon termination without cause, to exercise the vested portion of an option post-termination for up to ten years after the grant date (the life of the option). Option awards granted in the current period also include this provision. Effective September 30, 2011, the Company ceased using the simplified method for share-based compensation expense and now estimates the expected term for each award to approximate its contractual term. The Company determined the effect of the modification to be approximately $633,000, based upon the difference in the fair market value of the options immediately before and after the modification occurred. For the year ended June 30, 2013, the Company recorded modification charges to research and development and to general and administrative expenses of approximately $16,000 and $49,000, respectively. For the year ended June 30, 2012, the Company recorded modification charges to research and development and to general and administrative expenses of approximately $17,000 and $552,000, respectively.

On February 29, 2012, the Company’s former Chief Scientific Officer terminated his employment with the Company and became a consultant to the Company as its Chief Scientific Advisor effective March 1, 2012. As Chief Scientific Officer, this individual received on February 25, 2010 an option grant to purchase 500,000 shares of common stock at an exercise price of $0.87, of which 200,000 options were vested at the time employment ceased. As compensation for the prospective role of Chief Scientific Advisor, the 300,000 unvested options were allowed to continue to vest in accordance with the original terms of the option grant, which vested ratably on the anniversary of the date of grant over a five year service period. The fair market value of the non-employee portion of option grant was initially estimated at $234,000. Options granted to non-employees are required to be marked-to-market each reporting period and their value will fluctuate accordingly. The grant will continue to be expensed over the remainder of the original five year service period.

Warrants

In July 2012, the Company issued 100,000 fully vested warrants to a consultant as payment for investor relations services. These warrants have an exercise price of $1.00 per share and expire two years from the date of issuance. In October 2011, the Company issued 100,000 fully vested warrants to a consultant for investor relations services. These warrants have an exercise price of $2.00 per share and expire two years from the date of issuance. The grant date fair values of approximately $33,000 and $71,000, respectively, were determined using the Black-Scholes option pricing model with similar inputs to those used to value stock options, with the exception of the expected term.

XML

Document And Entity Information (USD $)	12 Months Ended
	Jun. 30, 2013	Sep. 10, 2013	Dec. 31, 2012
Document Information [Line Items]
Entity Registrant Name	iBio, Inc.
Entity Central Index Key	0001420720
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	IBIO
Entity Common Stock, Shares Outstanding		56,692,095
Document Type	10-K/A
Amendment Flag	true
Amendment Description	Amendment Description
Document Period End Date	Jun. 30, 2013
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2013
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 18,250,000

XML

Income Taxes

12 Months Ended

Jun. 30, 2013

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

14. Income Taxes

The components of the provision for income taxes consist of the following (in thousands):

	For the Years Ended June 30,
	2013		2012
Current - Federal and state	$	-	$	-
Deferred - Federal		(2,447)		(2,802)
Deferred - State		(366)		(417)
Total		(2,813)		(3,219)
Change in valuation allowance		2,813		3,219
Income tax expense	$	-	$	-

The Company has deferred income taxes due to income tax credits, net operating loss carryforwards, and the effect of temporary differences between the carrying values of certain assets and liabilities for financial reporting and income tax purposes.

The components of the Company’s deferred tax assets and liabilities are as follows (in thousands): 

	As of June 30,
	2013		2012
Deferred tax assets (liabilities):
Net operating loss	$	10,856	$	8,532
Share-based compensation		3,198		2,682
Research and development tax credits		737		400
Accounts payable amounts not currently deductible		-		140
Intangible assets		(56)		172
Vacation accrual		18		14
Other		-		-
Valuation allowance		(14,753)		(11,940)
Total	$	-	$	-

The Company has a valuation allowance against the full amount of its net deferred tax assets due to the uncertainty of realization of the deferred tax assets due to operating loss history of the Company. The Company currently provides a valuation allowance against deferred taxes when it is more likely than not that some portion, or all of its deferred tax assets will not be realized. The valuation allowance could be reduced or eliminated based on future earnings and future estimates of taxable income.

Federal net operating losses of approximately $5.5 million were used by the Former Parent prior to June 30, 2008 and are not available to the Company. The Former Parent allocated the use of the Federal net operating losses available for use on its consolidated Federal tax return on a pro rata basis based on all of the available net operating losses from all the entities included in its control group.

Federal and state net operating losses of approximately $28.9 and $17.7 million, respectively, are available to the Company as of June 30, 2013 and will expire at various dates through 2033. These carryforwards could be subject to certain limitations in the event there is a change in control of the Company pursuant to Internal Revenue Code Section 382, though the Company has not performed a study to determine if the loss carryforwards are subject to these Section 382 limitations. The Company has a research and development credit of approximately $737,000 at June 30, 2013.

A reconciliation of the statutory tax rate to the effective tax rate is as follows:

	Years Ended June 30,
	2013			2012
Statutory Federal income tax rate		34	%		34	%
State (net of Federal benefit)		6	%		6	%
Non-deductible expenses - change in fair value of derivative financial liability		3	%		26	%
Research and development tax credit		4	%		7	%
Non utilization of state operating loss (1)		-			(12)	%
Other		(2)	%		(4)	%
Change in valuation allowance		(45)	%		(57)	%
Effective income tax rate		0	%		0	%

(1) During the year ended June 30, 2012, the Company ceased doing business in a state and received a tax clearance. As a result, the cumulative net operating losses are not being recognized in the audited financial statements.

The Company has not been audited by the Internal Revenue Service or any states in connection with income taxes. The Company files federal and state income tax returns subject to varying statutes of limitations. The 2008 through 2012 tax returns generally remain open to examination by federal and state tax authorities.